Search
Arylacenamide
go.drugbank.com/drugs/DB05792ExperimentalArylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
Domiphen
go.drugbank.com/drugs/DB11594ApprovedDomiphen bromide is a quaternary ammonium compound that is predominantly employed as a topically administered antiseptic agent.
Synonyms: 1-dodecanaminium, n,n-dimethyl-n-(2-phenoxyethyl)Edaxeterkib
go.drugbank.com/drugs/DB21490InvestigationalEdaxeterkib is under investigation in clinical trial NCT03051035 (First-in-Human Study of KO-947 in Non-Hematological Malignancies). Edaxeterkib has a monoisotopic molecular weight of 469.22 Da.
Darusentan
go.drugbank.com/drugs/DB04883InvestigationalDarusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
ZEN-012
go.drugbank.com/drugs/DB06042ExperimentalZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition.
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906
Ebastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Products: EVASTEL Z